Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease

Chest

Volumn 146, Issue 2, 2014, Pages 276-282

  Wallace Jr , Richard J ^a,b   Brown Elliott, Barbara A ^a,b   McNulty, Steven ^a   Philley, Julie V ^b   Killingley, Jessica ^a   Wilson, Rebecca W ^a   York, Deanna S ^a   Shepherd, Sara ^a   Griffith, David E ^b  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Baylor UT Houston Center for AIDS Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; RIFABUTIN; RIFAMPICIN;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT DISEASE; REINFECTION; RETROSPECTIVE STUDY; SPUTUM SMEAR; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHIECTASIS; CLARITHROMYCIN; DNA, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LUNG DISEASES; MACROLIDES; MALE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME;

EID: 84902109958     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2538     Document Type: Article

References (39)

1. Bates JH. Mycobacterium avium disease: progress at last. Am J Respir Crit Care Med. 1996;153(6 pt 1):1737-1738.
2. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994;121(12):905-911.
3. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP; Clarithromycin Study Group of France. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest. 1995;107(4):1035-1040.
4. Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994;149(5):1335-1341. (Pubitemid 24147078)
5. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153(6 pt 1):1766-1772. (Pubitemid 26187897)
6. Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis. 1996;23(5):983-989. (Pubitemid 26367481)
7. Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis. 1998;178(1):121-126. (Pubitemid 28328084)
8. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000;30(2):288-292. (Pubitemid 30131535)
9. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160(3):866-872. (Pubitemid 29442022)
10. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;56(3):167-172.
11. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother. 2006;12(4):195-202. (Pubitemid 44327188)
12. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease [published online ahead of print November 19, 2010]. J Infect. doi:10.1016/j.jinf.2010.11.011 [withdrawn].
13. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother. 2012;18(4):436-443.
14. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989;321(13):863-868. (Pubitemid 19238618)
15. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178(10):1066-1074.
16. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185(5):575-583.
17. Wallace RJ Jr, Zhang Y, Brown BA, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med. 1998;158(4):1235-1244. (Pubitemid 28489028)
18. Wallace RJ Jr, Zhang Y, Brown-Elliott BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis. 2002;186(2):266-273. (Pubitemid 34765517)
19. Wallace RJ Jr, Glassroth J, Griffith DE, Olivier KN, Cook JL, Gordin F. American Thoracic Society, Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156(2)(suppl):S1- S25.
20. Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [published correction appears in Am J Respir Crit Care Med. 2007;175(7):744-745]. Am J Respir Crit Care Med. 2007;175(4):367-416. (Pubitemid 46271561)
21. Susceptibility Testing of Mycobacteria, Norcardiae, and Other Aerobic Actinomycetes; Approved Standard. Wayne, PA: Clinical and Laboratory Standards Institute; 2003. NCCLS document M24-A.
22. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard-Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI document M24-A2.
23. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004;126(2):566-581. (Pubitemid 39093445)
24. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 1993;16(3):215-221. (Pubitemid 23107304)
25. Brown BA, Wallace RJ Jr, Griffith DE, Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis. 1995;20(4):1073-1074.
26. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995;171(3):747-750.
27. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995;21(3):594-598.
28. Griffith DE, Brown BA, Wallace RJ Jr. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus - negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. Clin Infect Dis. 1996;23(6):1321-1322. (Pubitemid 26423180)
29. Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis. 1997;24(5):958-964. (Pubitemid 27193885)
30. Brown BA, Wallace RJ Jr, Griffith DE, Warden R. Clarithromycin-associated digoxin toxicity in the elderly. Clin Infect Dis. 1997;24(1):92-93. (Pubitemid 27023688)
31. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538-1544. (Pubitemid 38738547)
32. Iakhiaeva E, McNulty S, Brown Elliott BA, et al. Mycobacterial interspersed repetitive-unit-variable-number tandem-repeat (MIRU-VNTR) genotyping of Mycobacterium intracellulare for strain comparison with establishment of a PCR-based database. J Clin Microbiol. 2013;51(2):409-416.
33. Nishiuchi Y, Maekura R, Kitada S, et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis. 2007;45(3):347-351. (Pubitemid 47101032)
34. Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011;17(3):419-424.
35. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928-934. (Pubitemid 44564794)
36. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(3):545-582.
37. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012;15(3):149-161.
38. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970-976.
39. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977-982.